Subscribe
handshake-agreement
Rawpixel.com / Shutterstock, Inc
17 November 2016Americas

BMS and Enterome collaborate over immuno-oncology

Bristol-Myers Squibb and Enterome, a pharmaceutical development and diagnostic company, have entered into a collaboration agreement focusing on immuno-oncology.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
BMS pays $1.85bn for immuno-oncology programme
15 February 2018   Bristol-Myers Squibb has agreed to pay $1.85 billion for an immuno-oncology programme.
Americas
BMS sues over generic of blockbuster leukaemia treatment
4 October 2021   Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.


Editor's picks

Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024

Editor's picks

Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024

More on this story

Americas
BMS pays $1.85bn for immuno-oncology programme
15 February 2018   Bristol-Myers Squibb has agreed to pay $1.85 billion for an immuno-oncology programme.
Americas
BMS sues over generic of blockbuster leukaemia treatment
4 October 2021   Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.

More on this story

Americas
BMS pays $1.85bn for immuno-oncology programme
15 February 2018   Bristol-Myers Squibb has agreed to pay $1.85 billion for an immuno-oncology programme.
Americas
BMS sues over generic of blockbuster leukaemia treatment
4 October 2021   Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.

More features

Preventative IP for preventative pharma healthcare
Court denies Regeneron bid to halt copy of blockbuster eye drug
Interview: Klaus Grabinski, UPC Court of Appeal president
Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy